PainReform Ltd. (PRFX)
NASDAQ: PRFX · Real-Time Price · USD
2.190
-0.110 (-4.78%)
At close: Apr 3, 2025, 4:00 PM
2.260
+0.070 (3.20%)
Pre-market: Apr 4, 2025, 8:24 AM EDT
PainReform Employees
PainReform had 7 employees as of December 31, 2023. The number of employees increased by 1 or 16.67% compared to the previous year.
Employees
7
Change (1Y)
1
Growth (1Y)
16.67%
Revenue / Employee
n/a
Profits / Employee
-$2,524,714
Market Cap
1.92M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7 | 1 | 16.67% |
Dec 31, 2022 | 6 | 2 | 50.00% |
Dec 31, 2021 | 4 | 2 | 100.00% |
Dec 31, 2020 | 2 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
PRFX News
- 4 weeks ago - PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics - GlobeNewsWire
- 6 weeks ago - PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity - GlobeNewsWire
- 3 months ago - PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110 - GlobeNewsWire
- 4 months ago - PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial - GlobeNewsWire
- 5 months ago - PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement - GlobeNewsWire
- 7 months ago - PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110 - GlobeNewsWire
- 7 months ago - PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds - GlobeNewsWire
- 8 months ago - PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study - GlobeNewsWire